Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Article CommentaryCommentary

Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency Data

Paul Wu, Taymar Hartman, Louise Almond, Jennitte Stevens, John Thrift, Juhi Ojha, Christina Alves, David Shaw, Michael W. Laird, Robyn Emmins, Yuan Zhu, Ren Liu, Zhimei Du, Rolf Koehler, Thomas Jostock, Karin Anderson, Chris Campbell and Howard Clarke
PDA Journal of Pharmaceutical Science and Technology March 2020, 74 (2) 264-274; DOI: https://doi.org/10.5731/pdajpst.2018.009316
Paul Wu
1Bayer HealthCare LLC, Berkeley, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paul.wu@bayer.com
Taymar Hartman
2Abbvie Biotherapeutics Inc., Redwood City, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Almond
3Allergan Biologics Ltd., Liverpool, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennitte Stevens
4Amgen Inc., Thousand Oaks, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Thrift
1Bayer HealthCare LLC, Berkeley, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juhi Ojha
1Bayer HealthCare LLC, Berkeley, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Alves
5Biogen Inc., Cambridge, MA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Shaw
6Genentech Inc., South San Francisco, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Laird
6Genentech Inc., South San Francisco, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robyn Emmins
7GSK, King of Prussia, PA; Stevenage, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Zhu
7GSK, King of Prussia, PA; Stevenage, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ren Liu
8Merck & Co., Inc., Kenilworth, NJ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhimei Du
8Merck & Co., Inc., Kenilworth, NJ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf Koehler
9Novartis Pharma AG, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Jostock
9Novartis Pharma AG, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Anderson
10Pfizer Inc., Andover, MA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Campbell
11Takeda Pharmaceuticals, Cambridge, MA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard Clarke
12Seattle Genetics Inc., Bothell, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 74 no. 2 264-274
DOI 
https://doi.org/10.5731/pdajpst.2018.009316
PubMed 
31519780

Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online April 9, 2020.

Article Versions

  • previous version (September 13, 2019 - 09:11).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© PDA, Inc. 2020

Author Information

  1. Paul Wu1,*,
  2. Taymar Hartman2,
  3. Louise Almond3,
  4. Jennitte Stevens4,
  5. John Thrift1,
  6. Juhi Ojha1,
  7. Christina Alves5,
  8. David Shaw6,
  9. Michael W. Laird6,
  10. Robyn Emmins7,
  11. Yuan Zhu7,
  12. Ren Liu8,
  13. Zhimei Du8,
  14. Rolf Koehler9,
  15. Thomas Jostock9,
  16. Karin Anderson10,
  17. Chris Campbell11,# and
  18. Howard Clarke12
  1. 1Bayer HealthCare LLC, Berkeley, CA;
  2. 2Abbvie Biotherapeutics Inc., Redwood City, CA;
  3. 3Allergan Biologics Ltd., Liverpool, UK;
  4. 4Amgen Inc., Thousand Oaks, CA;
  5. 5Biogen Inc., Cambridge, MA;
  6. 6Genentech Inc., South San Francisco, CA;
  7. 7GSK, King of Prussia, PA; Stevenage, UK;
  8. 8Merck & Co., Inc., Kenilworth, NJ;
  9. 9Novartis Pharma AG, Basel, Switzerland;
  10. 10Pfizer Inc., Andover, MA;
  11. 11Takeda Pharmaceuticals, Cambridge, MA; and
  12. 12Seattle Genetics Inc., Bothell, WA
  1. ↵*Corresponding Author: Paul Wu, Bayer HealthCare LLC, Berkeley, CA 94710, e-mail: paul.wu{at}bayer.com
  • ↵# Current affiliation: Sarepta Therapeutics, Cambridge, MA, USA.

View Full Text

Cited By...

  • 1 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Retrospective assessment of clonal origin of cell lines
    Erik Langsdorf, Le Yu, Lioudmila Kanevskaia, Roland Felkner, Stephen Sturner, Duncan McVey, Anurag Khetan
    Biotechnology Progress 2021
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 74 (2)
PDA Journal of Pharmaceutical Science and Technology
Vol. 74, Issue 2
March/April 2020
  • Table of Contents
  • Index by Author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency Data
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency Data
Paul Wu, Taymar Hartman, Louise Almond, Jennitte Stevens, John Thrift, Juhi Ojha, Christina Alves, David Shaw, Michael W. Laird, Robyn Emmins, Yuan Zhu, Ren Liu, Zhimei Du, Rolf Koehler, Thomas Jostock, Karin Anderson, Chris Campbell, Howard Clarke
PDA Journal of Pharmaceutical Science and Technology Mar 2020, 74 (2) 264-274; DOI: 10.5731/pdajpst.2018.009316

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Advancing Biologics Development Programs with Legacy Cell Lines: Advantages and Limitations of Genetic Testing for Addressing Clonality Concerns Prior to Availability of Late Stage Process and Product Consistency Data
Paul Wu, Taymar Hartman, Louise Almond, Jennitte Stevens, John Thrift, Juhi Ojha, Christina Alves, David Shaw, Michael W. Laird, Robyn Emmins, Yuan Zhu, Ren Liu, Zhimei Du, Rolf Koehler, Thomas Jostock, Karin Anderson, Chris Campbell, Howard Clarke
PDA Journal of Pharmaceutical Science and Technology Mar 2020, 74 (2) 264-274; DOI: 10.5731/pdajpst.2018.009316
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • 1. Opinion on Additional Genetic Testing
    • 2. Current Genetic Testing for BLA
    • 3. Genetic Technologies Supporting Assurance of Clonality
    • 4. Further Discussion and Conclusions
    • Conflict of Interest Declaration
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Ridding the World of 'Rogues': Improving Vapor Phase H2O2 Sterilization and Decontamination Processes
  • Something for Nothing
  • MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility
Show more Commentary

Similar Articles

Keywords

  • Chinese hamster ovary (CHO)
  • Production cell line
  • Cell line development
  • Genetic characterization
  • Master Cell Bank (MCB)
  • Working Cell Bank (WCB)
  • Clonal derivation
  • Clonality
  • Clonal
  • IND
  • BLA

>

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2023 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire